Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients　– Optical Coherence Tomography Analysis –

Hong, Soon Jun; Choi, Seung Cheol; Cho, Jae-Young; Joo, Hyung Joon; Park, Jae Hyoung; Yu, Cheol Woong; Lim, Do Sun

doi:10.1253/circj.cj-14-0964

Cited by 16 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ann Transl Med 2016;4(12):236 atm.amegroups.com intima-media thickness, further suggesting a kidneyindependent clearance of these miRNAs (68,76). Neointimal hyperplasia after coronary artery stenting, and its response to therapy after oral pioglitazone, an insulin sensitizer, was found to correlate with serum levels of miRNA-24 in 72 diabetic patients (77). This short ncRNA is a regulator of cytokine synthesis in macrophages, and migration in aortic smooth muscle cells (78).…”

Section: Diabetic Vascular Manifestationsmentioning

confidence: 97%

Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease

2016

View full text Add to dashboard Cite

Non-coding RNA (ncRNA) is a class of genetic, epigenetic and translational regulators, containing short and long transcripts with intriguing abilities for use as biomarkers due to their superordinate role in disease development. In the past five years many of these have been investigated in cardiovascular diseases (CVD), mainly myocardial infarction (MI) and heart failure. To extend this view, we summarize the existing data about ncRNA as biomarker in the whole entity of CVDs by literature-based review and comparison of the identified candidates. The myomirs miRNA-1, -133a/b, -208a, -499 with well-defined cellular functions have proven equal to classic protein biomarkers for disease detection in MI. Other microRNAs (miRNAs) were reproducibly found to correlate with disease, disease severity and outcome in heart failure, stroke, coronary artery disease (CAD) and aortic aneurysm. An additional utilization has been discovered for therapeutic monitoring. The function of long non-coding transcripts is only about to be unraveled, yet shows great potential for outcome prediction. ncRNA biomarkers have a distinct role if no alternative test is available or has is performing poorly. With increasing mechanistic understanding, circulating miRNA and long non-coding transcripts will provide useful disease information with high predictive power.

show abstract

Section: Diabetic Vascular Manifestationsmentioning

confidence: 97%

Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease

2016

View full text Add to dashboard Cite

show abstract

“…The IRIS trial discovered that the cardioprotective effect of pioglitazone was considerable even in prediabetes patients, whereby a 24% risk reduction in stroke and myocardial infarction was observed among those treated with pioglitazone compared to placebo [96]. Moreover, in patients who had undergone percutaneous coronary intervention, pioglitazone effectively suppressed in-stent neointimal hyperplasia besides reducing restenosis and incidence of target lesion revascularization [97][98][99][100]. Compared to sulfonylurea, the therapeutic effect of pioglitazone in delaying atherosclerotic progression is superior as exemplified by the lower carotid artery intima-media thickness and atheroma volume [101][102][103].…”

Section: Cardiovascular Diseases (Cvds)mentioning

confidence: 99%

“…Increased circulating miRNA-24 and flow-mediated dilation [97] NA (96) Reduced neointimal hyperplasia in patients with myocardial infarction treated with primary stent implantation [98] NA 97Suppressed in-stent neointimal proliferation…”

Section: Cardiovascular Diseases (Cvds)mentioning

confidence: 99%

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

Cheng

Tan

Low

et al. 2019

IJMS

178

152

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.

show abstract

“…A subsequent prospective study showed that pioglitazone significantly decreased neointimal hyperplasia (NIH), accompanied by increases in circulating miR-24. We can infer that decreased miR-24 might be associated with increased NIH in patients with T2DM [50]. …”

Section: Clinical Studies On Micrornas In Cvd In Diabetesmentioning

confidence: 99%

MicroRNAs and Cardiovascular Disease in Diabetes Mellitus

Ding

Sun

2017

BioMed Research International

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the major macrovascular complication of diabetes mellitus. Recently, although CVD morbidity and mortality have decreased as a result of comprehensive control of CVD risk factors, CVD remains the leading cause of death of patients with diabetes in many countries, indicating the potential underlying pathophysiological mechanisms. MicroRNAs are a class of noncoding, single-stranded RNA molecules that are involved in β-cell function, insulin secretion, insulin resistance, skeletal muscle, and adipose tissue and which play an important role in glucose homeostasis and the pathogenesis of diabetic complications. Here, we review recent progress in research on microRNAs in endothelial cell and vascular smooth muscle cell dysfunction, macrophage and platelet activation, lipid metabolism abnormality, and cardiomyocyte repolarization in diabetes mellitus. We also review the progress of microRNAs as potential biomarkers and therapeutic targets of CVD in patients with diabetes.

show abstract

Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients　– Optical Coherence Tomography Analysis –

Cited by 16 publications

References 34 publications

Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease

Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

MicroRNAs and Cardiovascular Disease in Diabetes Mellitus

Contact Info

Product

Resources

About

Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients – Optical Coherence Tomography Analysis –

Cited by 16 publications

References 34 publications

Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease

Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease

Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

MicroRNAs and Cardiovascular Disease in Diabetes Mellitus

Contact Info

Product

Resources

About

Pioglitazone Increases Circulating MicroRNA-24 With Decrease in Coronary Neointimal Hyperplasia in Type 2 Diabetic Patients　– Optical Coherence Tomography Analysis –